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Objectives
To determine the minimal accepted sensitivity (MAS) of a
urine biomarker that patients are willing to accept to replace
cystoscopy and to assess qualitatively their views and reasons.
Patients and Methods
Patients were part of a prospective multicentre observational
study recruiting people with bladder cancer for a urine
biomarker study (DETECT II; ClinicalTrials.gov:
NCT02781428). A mixed-methods approach comprising (1) a
questionnaire to assess patients’ experience with cystoscopy
and patients’ preference for cystoscopy vs urinary biomarker,
and (2) semi-structured interviews to understand patient
views, choice and reasons for their preference.
Results
A urine biomarker with an MAS of 90% would be accepted
by 75.8% of patients. This was despite a high self-reported
prevalence of haematuria (51.0%), dysuria/lower urinary tract
symptoms (69.1%) and urinary tract infection requiring
antibiotics (25.8%). There was no association between MAS
with patient demographics, adverse events experienced,
cancer characteristics or distance of patients’ home to
hospital. The qualitative analysis suggested that patients
acknowledge that cystoscopy is invasive, embarrassing and
associated with adverse events but are willing to tolerate the
procedure because of its high sensitivity. Patients have
conﬁdence in cystoscopy and appreciate the visual diagnosis
of cancer. Both low- and high-risk patients would consider a
biomarker with a reported sensitivity similar to that of
cystoscopy.
Conclusion
Patients value the high sensitivity of cystoscopy despite the
reported discomfort and adverse events experienced after it.
The sensitivity of a urinary biomarker must be close to
cystoscopy to gain patients’ acceptance.
Keywords
biomarker, diagnostic, patient-reported outcome measure,
questionnaires, semi-structured interviews, #BladderCancer,
#blcsm
Introduction
Bladder cancer is diagnosed in 8.0% of patients presenting
with haematuria and, at initial diagnosis, 75% of cases are
non-muscle-invasive bladder cancer (NMIBC) [1,2]. Patients
with NMIBC have a 28–50% risk of recurrence and a 5–20%
risk of progression at 5 years [3]. The risk of recurrence
necessitates regular surveillance cystoscopy, and guidelines
recommend a risk-adapted approach which can be as
frequent as 3-monthly cystoscopy, with lifelong follow-up for
high-risk disease [4]. The requirement for vigilant surveillance
strategies is responsible for the high cost of healthcare
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associated with bladder cancer [5]. Cystoscopy has a
sensitivity of 98% for detection of bladder cancer although it
remains an invasive procedure associated with patient
discomfort and a 5% risk of UTI [6,7].
The potential for urinary biomarkers for the detection of
bladder cancer is an area of active research, and several
biomarkers have been approved for use. Commercially
available tests are licensed only as companion tests as they
do not have the required diagnostic performance to
replace cystoscopy (sensitivities of 57–82%) [8]. Novel
urinary biomarkers have reported high sensitivities but
often lack robust prospective validation [9,10]. Regardless
of the performance of current or future urinary-based
biomarkers, it is essential to understand patient perception
and willingness to forgo cystoscopy for non-invasive
testing.
To understand patient views relating to cystoscopy and the
potential to integrate urinary-based biomarkers into a
surveillance programme, we conducted a multicentre
prospective observational study in which patients with
NMIBC completed a questionnaire to determine the minimal
accepted sensitivity (MAS) of a urine biomarker and we
explored patients’ willingness to accept a biomarker rather
than cystoscopy. We also report patient experience and
adverse events during or after ﬂexible cystoscopy. Reasons for
preference were assessed through a qualitative analysis using
semi-structured interviews.
Methods
Study Design
Between September 2016 and April 2017, a total of 370
patients with histologically conﬁrmed NMIBC and a
minimum of 6 months’ (two surveillance cystoscopies and
two urine collection for biomarker testing) follow-up were
recruited from 52 UK hospitals. Patients were sent
questionnaires by post and 213 patients (57.6%) returned
completed questionnaires. A total of 20 English-speaking
patients from this cohort consented to participate in a semi-
structured telephone interview. Of these patients, four (20%)
had low-grade cancers to ensure adequate representation of
NMIBC. The full study protocol has been previously
described [11]. The reported study represents a secondary
endpoint for the DETECT II study (clinicaltrials.gov:
NCT02781428).
Patient demographics, education level attained, and history of
bladder cancer were recorded. Cancer stage was assessed
using TNM WHO cancer classiﬁcation [12]. Cancer risk was
assessed using the European Association of Urology (EAU)
risk classiﬁcation [1]. Distance from patients’ home to local
hospital by private transport was calculated using www.ma
ps.google.com.
Patient Questionnaire
We constructed a patient experience questionnaire after
consultation with the UCL Health Behaviour Research Centre
(author M.H.) as no validated questionnaire exists. The
questionnaire domains assessed overall experience of
cystoscopy, anxiety preceding cystoscopy and pain
experienced, using a ﬁve-point Likert-scale. Preference for
cystoscopy or urinary biomarker was assessed using the
standard gamble method [13]. Cystoscopy was deﬁned as
having a sensitivity of 98% [6]. The MAS for a urinary
biomarker was deﬁned as the sensitivity at which patients
expressed either a preference for a urine biomarker or were
neutral about accepting either the biomarker or cystoscopy.
Qualitative Semi-Structured Interview
Each qualitative semi-structured interview lasted between 20
and 40 min. All interviews were carried out by one
interviewer and patients were approached after a minimum of
6 months’ follow-up from initial cancer diagnosis. The
interview was designed to explore the following: experience of
cystoscopy; perceived advantages and disadvantages of
cystoscopy; perceived advantages and disadvantages of a urine
biomarker; reasons for the preference for cystoscopy or a
urine biomarker; perceived acceptable sensitivity of a urine
biomarker for detection of bladder cancer; and preference for
a surveillance pathway combining a urine biomarker
interspaced with cystoscopy.
Statistical Methods and Data Analysis
Continuous data were reported using descriptive statistics
such as mean, median, interquartile range and 95% CI.
Categorical variables were compared using the chi-squared
test. The t-test and ANOVA were used to compare the mean of
continuous variables. SPSS v22 (IBM Corp, Armonk, New
York, NY, USA) was used for statistical analysis and
statistical signiﬁcance was set at P < 0.05.
Patient interviews were performed using Skype (Microsoft,
Redmond, WA, USA) and recorded using an Evaer Skype
recorder. Interview recordings were transcribed, and data were
managed using Nvivo 11 (QSR International, Melbourne, Vic.,
Australia). A thematic analysis was used, open coding was
performed by two researchers (W.S.T. and C.H.T.) on the ﬁrst
two transcripts and differences were resolved by discussion.
Codes were assigned to sentences/paragraphs of transcripts
based on the study objective. Axial coding was performed, and
existing codes combined to create larger themes. One
researcher (W.S.T.) continued to code remaining transcripts
and any new emerging codes were discussed. Comparisons
were made throughout the analysis to form the ﬁnal
framework. Background notes throughout all study phases were
reviewed to avoid potential bias in reporting.
© 2019 The Authors
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Ethics and Informed Consent
The corresponding author certiﬁes that, when applicable, a
statement(s) has been included in the manuscript
documenting institutional review board, ethics committee or
ethical review board study approval; principles of Helsinki
Declaration were followed in lieu of formal ethics
committee approval; institutional animal care and use
committee approval; all human subjects provided written
informed consent was obtained from all patients. DETECT
II study protocol received Health Research Authority:
London-Stanmore Research Ethics Committee approval on
30 August 2016 (IRAS project ID: 203022, REC reference:
16/LO/1044). This trial is registered on clinicaltrials.gov:
NCT02781428.
Results
Patient Demographics
A patient cohort ﬂow diagram is shown in Fig. S1. Baseline
characteristics and clinical-pathological variables for 213
patients are shown in Table 1. The median patient age was
74.0 years and 167 patients (78.4%) were men. Patients with
a primary diagnosis of NMIBC in the preceding 6 months
accounted for 62.9% of the cohort (n = 134). A total of 74.1%
of patients (n = 158) had ≤5 previous cystoscopies. High-risk
NMIBC according to EAU risk classiﬁcation was conﬁrmed
in 40.3% of patients (n = 83), but only 17.8% of patients (n =
38) perceived their cancer as high risk.
Patient-Reported Adverse Events
The majority of patients experienced an adverse event after
cystoscopy, with 77.5% (n = 165) reporting ≥1 adverse event
(Table 2). The self-reported prevalence of haematuria,
dysuria/LUTS and UTI requiring antibiotics after cystoscopy
was 46.9% (n = 100), 67.1% (n = 143) and 23.1% (n = 51),
respectively. The signiﬁcance of symptoms after cystoscopy is
highlighted by the fact that 13.4% of patients had an
unpleasant experience after the procedure. Moderate to
signiﬁcant pain was reported by 11.5% of patients and 10.0%
of patients reported moderate to signiﬁcant anxiety preceding
cystoscopy (Fig. 1).
Minimum Acceptable Sensitivity for a Urine
Biomarker to Replace Cystoscopy
A total of 78.6% (n = 163) of patients would be happy to
use a urine biomarker if it was as sensitive as cystoscopy
(Table 3), with 24.2% of patients prepared to accept a
urine biomarker even if sensitivity was as low as 85%.
There was no relation between patient experience of
cystoscopy and MAS. Most patients (74.2%, n = 158)
would accept the option to interspace cystoscopy with a
urine biomarker to extend the time interval between
surveillance cystoscopies.
Table 1 Patient demographics and clinical-pathological variables (N =
213).
Variable
Age, median (IQR), years 74.0 (67.1–81.1)
Men, n (%) 170 (79.8)
Highest education level, n (%)
No formal education 8 (3.8)
High school 56 (26.3)
GCSE 39 (18.3)
A-level 20 (9.4)
University or higher degree 31 (14.6)
Not known 59 (27.7)
Smoking history, n (%)
Non-smoker 56 (26.3)
Ex-smoker 129 (60.6)
Current smoker 18 (8.5)
Not known 10 (4.7)
Ethnicity, n (%)
White 188 (88.3)
Non-white 6 (2.8)
Not known 19 (8.9)
Employment, n (%)
Full time/part-time/home maker/voluntary 45 (21.1)
Retired 161 (75.6)
Disability/unemployed 4 (1.9)
Missing 3 (1.4)
New or recurrent tumour, n (%)
New 135 (63.4)
Recurrence 78 (36.6)
Procedure, n (%)
TURBT/bladder biopsy 206 (96.7)
Cystodiathermy 7 (3.3)
Previous cystoscopies, n (%)
≤2 66 (31.0)
2–5 92 (43.2)
≥6 47 (22.1)
Not known 8 (3.8)
Tumour grade, n (%)
G1 36 (16.9)
G2 99 (46.5)
G3 71 (33.3)
Not known 7 (3.3)
Tumour stage, n (%)
CIS 3 (1.4)
pTa 156 (73.2)
pT1 47 (22.1)
Not known 7 (3.3)
Papillary with concurrent CIS, n (%) 5 (2.4)
Disease risk, n (%)
Low 18 (8.5)
Intermediate 105 (49.3)
High 83 (39.0)
Not known 7 (3.3)
Patients perception of disease risk, n (%)
Low 49 (23.0)
Intermediate 112 (52.6)
High 38 (17.8)
Not known 14 (6.6)
CIS, carcinoma in situ.
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There was no difference in MAS according to patient
demographics, previous adverse events or experience during
or after cystoscopy, cancer characteristics or distance to
hospital from home (Table 4). There was a trend towards
signiﬁcance between a lower MAS for men (P = 0.052) and
patients without a recurrence in the previous 6 months (P =
0.078; Table 4). Patient conﬁdence in the accuracy of
cystoscopy was the top reason for choosing cystoscopy
(70.5%), followed by reassurance by a clinician (51.9%) and a
preference for a diagnostic test performed in hospital (51.4%;
Table S1). The top reasons for choosing a urine biomarker
was previous discomfort after cystoscopy (30.5%), avoiding a
hospital visit (28.6%) and the non-invasive nature of the test
(28.1%).
Qualitative Analysis
The demographics and tumour characteristics of the 20
patients interviewed are shown in Table S2. Main themes that
emerged are shown in Table 5.
Views and Experience of Cystoscopy
Patients appreciate the fact that cystoscopy provides a visual
diagnosis of cancer and attributed this to a presumed near-
perfect sensitivity for the detection of bladder cancer. While
patients did not like cystoscopy, they were prepared to
tolerate it because of its good diagnostic ability. Patients also
valued the fact that cystoscopy provides an instant diagnosis
and appreciated that a healthcare professional performs the
cystoscopy.
Patient perception of passing a cystoscope along the urethra
was that it can be disturbing, although they recognize the
requirement to visualize the bladder. Some patients described
the procedure as embarrassing and felt violated after
cystoscopy. Patients also appreciate that cystoscopy performed
by an experienced urologist would reduce adverse events and
patient discomfort.
Table 2 Complications experienced after cystoscopy (n = 213).
Adverse event n (%)
Any adverse event
Yes 165 (77.5)
No 47 (22.1)
Not known 1 (0.4)
Haematuria
Yes 100 (46.9)
No 96 (45.1)
Not known 17 (8.0)
Dysuria/urinary symptoms
Yes 143 (67.1)
No 64 (30.0)
Not known 6 (2.8)
UTI requiring antibiotics
Yes 51 (23.9)
No 147 (69.1)
Not known 15 (7.0)
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Fig. 1 Patient experience after cystoscopy: (A) overall experience, (B)
pain during cystoscopy, (C) anxiety preceding cystoscopy. 1 denotes no
symptoms/painless/not anxious. 5 denotes severe symptoms/very
painful/very anxious.
Table 3 Minimal acceptable sensitivity for acceptance of urinary
biomarker.
MAS n (%)
85% 50 (23.5)
90–95% 26 (12.2)
96–97% 30 (14.1)
98% 57 (26.8)
Preference for cystoscopy regardless of accuracy of cystoscopy 44 (20.7)
Missing 6 (2.8)
MAS, minimal acceptable sensitivity.
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Table 4 Patient demographics and clinical-pathological variables stratiﬁed according to minimal acceptable sensitivity.
Variables Minimal acceptable sensitivity P
85% 90–95% 96–67% 98% Cystoscopy regardless
Median (IQR) age, years 73.4 (67.9–81.9) 71.6 (66.0–78.1) 72.7 (64.7–80.7) 75.5 (65.5–79.8) 76.9 (69.5–83.1) 0.486
Men 47 (94.0) 19 (73.1) 21 (70.0) 45 (78.9) 33 (75.0) 0.052
Highest education level
No formal education 0 (0) 1 (3.8) 1 (3.3) 4 (7.0) 2 (4.5) 0.165
High school 14 (28.0) 6 (23.1) 11 (36.7) 13 (22.8) 12 (27.1)
GCSE 6 (12.0) 4 (15.4) 5 (16.7) 16 (28.1) 7 (15.9)
A-level 4 (8.0) 5 (19.2) 3 (10.0) 4 (7.0) 2 (4.5)
University or higher degree 8 (16.0) 7 26.9) 2 (6.7) 9 (15.8) 4 (9.1)
Not known 18 (36.0) 3 (11.5) 8 (26.7) 11 (19.3) 17 (38.6)
Previous cystoscopies, n (%)
≤2 15 (30.0) 7 (26.9) 16 (53.3) 14 (24.6) 12 (27.3) 0.114
2–5 17 (34.0) 16 (61.5) 8 (26.7) 30 (52.6) 20 (45.5)
≥6 15 (30.0) 3 (11.5) 6 (20.0) 11 (19.3) 10 (22.7)
Not known 3 (6.0) 0 (0) 0 (0) 2 (3.5) 2 (4.5)
New or recurrent cancer
New 28 (58.0) 19 (73.1) 21 (70.0) 32 (56.1) 30 (68.2) 0.411
Recurrent 21 (42.0) 7 (26.9) 9 (30.0) 25 (43.9) 14 (31.8)
Previous recurrence within 6 months
Yes 30 (60.0) 20 (76.9) 17 (56.7) 39 (68.4) 28 (63.6) 0.078
No 10 (20.0) 4 (15.4) 11 (36.7) 13 (22.8) 15 (34.1)
Not known 10 (20.0) 2 (7.7) 2 (6.7) 5 (8.8) 1 (2.3)
Tumour grade
G1 9 (18.0) 8 (30.8) 5 (16.7) 9 (15.8) 5 (11.4) 0.231
G2 24 (48.0) 7 (26.9) 18 (60.0) 29 (50.9) 17 (38.6)
G3 15 (30.0) 11 (42.3) 6 (20.0) 16 (28.1) 21 (47.7)
Not known 2 (4.0) 0 (0) 1 (3.3) 3 (5.3) 1 (2.3)
Tumour stage
CIS 2 (4.0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0.428
pTa 40 (80.0) 17 (65.4) 21 (70.0) 43 (75.4) 30 (68.2)
pT1 6 (12.0) 9 (34.6) 8 (26.7) 10 (17.5) 13 (29.5)
Not known 2 (4.0) 0 (0) 1 (3.3) 3 (5.3) 1 (2.3)
Actual disease risk
Low 5 (10.0) 4 (15.4) 2 (6.7) 5 (8.8) 2 (4.5) 0.482
Intermediate 26 (52.0) 9 (34.9) 18 (60.0) 31 (54.4) 18 (40.9)
High 17 (34.0) 13 (50.0) 9 (30.0) 18 (31.6) 23 (52.3)
Not known 2 (4.0) 0 (0) 1 (3.3) 3 (5.3) 1 (2.3)
Patient’s presumed disease risk
Low 16 (32.0) 3 (11.5) 5 (16.7) 9 (15.8) 14 (31.8) 0.353
Intermediate 22 (44.0) 14 (53.8) 18 (60.0) 34 (59.6) 24 (54.5)
High 9 (18.0) 8 (30.8) 5 (16.7) 12 (21.1) 4 (9.1)
Not known 3 (6.0) 1 (3.8) 2 (6.7) 2 (3.5) 2 (4.5)
Any adverse event
Yes 41 (82.0) 17 (65.4) 23 (76.7) 45 (78.9) 36 (81.8) 0.504
No 9 (18.0) 9 (34.6) 7 (23.3) 12 (21.1) 8 (18.2)
Haematuria
Yes 28 (56.0) 11 (42.3) 12 (40.0) 24 (42.1) 22 (50.0) 0.484
No 20 (40.0) 14 (53.8) 14 (46.7) 30 (52.6) 17 (38.6)
Not known 2 (4.0) 1 (3.8) 4 (13.3) 3 (5.3) 6 (11.4)
Dysuria/LUTS
Yes 33 (66.0) 17 (65.4) 19 (63.3) 39 (68.4) 32 (72.7) 0.764
No 17 (34.0) 9 (34.6) 10 (33.3) 17 (29.8) 10 (22.7)
Not known 0 (0) 0 (0) 1 (3.3) 1 (1.8) 2 (4.5)
UTI requiring antibiotics
Yes 9 (18.0) 4 (15.4) 10 (33.3) 13 (22.8) 13 (29.5) 0.196
No 39 (78.0) 19 (73.1) 19 (63.3) 42 (73.7) 25 (56.8)
Not known 2 (4.0) 3 (11.5) 1 (3.3) 2 (3.5) 6 (13.6)
Overall experience
No symptoms 23 (46.0) 11 (42.3) 12 (41.4) 31 (54.4) 22 (51.2) 0.833
Neutral 20 (40.0) 9 (34.6) 13 (44.8) 19 (33.3) 17 (39.5)
Severe symptoms 7 (14.0) 6 (23.1) 4 (13.8) 7 (12.3) 4 (9.3)
Pain
Painless 24 (48.0) 13 (50.0) 15 (50.0) 27 (47.4) 27 (61.4) 0.82
Somewhat painless 19 (38.0) 9 (34.6) 11 (36.7) 22 (38.6) 15 (34.1)
Very painful 5 (10.0) 4 (15.4) 4 (13.3) 7 (12.3) 2 (4.5)
Not known 2 (4.0) 0 (0) 0 (0) 1 (1.8) 0 (0)
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Views and Experience of Urine Testing
Patients valued the convenience of a urine biomarker,
reducing the need to attend hospital and be subjected to a
procedure. Furthermore, patients appreciated that a urine
biomarker was free of adverse events, unlike cystoscopy, and
believed that a urine biomarker would allow earlier testing
and subsequently allow prompt commencement of
treatment.
Active Comparison Between Cystoscopy and Urine
Test
When comparing between cystoscopy and the urine
biomarker, patients were pragmatic and understood that no
test is 100% accurate. Patients prioritized the test with the
highest sensitivity and most would only accept a urine test
with a similar sensitivity to cystoscopy. Missing bladder
cancer during surveillance was a signiﬁcant worry to
patients, and patients with high-grade bladder cancer felt
particularly concerned about missing recurrence and
prioritized the high sensitivity of cystoscopy. Some
patients’ familiarity with cystoscopy and the fact that they
had a positive experience with cystoscopic detection of
cancer reinforced their preference for cystoscopy over a
urine test. An overarching theme was that patients were
not conﬁdent in the ability of a urine test to identify
bladder cancer with a high sensitivity as they perceived it
to be ‘experimental’ when compared to cystoscopy, the
current ‘gold standard’.
Patients who had previously experienced embarrassment
related to cystoscopy were willing to accept a lower
diagnostic sensitivity for a biomarker. All patients were
open to interspacing cystoscopy with a urine biomarker to
increase the interval between cystoscopies, although most
reinforced the requirement for comparable sensitivity.
Some patients expressed the opinion that a molecular urine
test may potentially identify cancers before they are
diagnosed visually. Further, some patients were skeptical
about the ability of a biomarker which would be able to
match cystoscopy.
Discussion
This represents the ﬁrst study to explore qualitatively the
views and decision-making of patients when considering
between cystoscopy and a urine biomarker for the detection
of bladder cancer recurrence. The majority of patients
(75.8%) recognized biomarker performance as important and
would discount any biomarker with MAS <90%; however,
63.3% of patients would accept a biomarker with a MAS of
≥95%, suggesting that patients’ willingness to accept a
biomarker is linked to its performance characteristics.
Nevertheless, 21.3% of patients would prefer cystoscopy
regardless of urine biomarker performance because of factors
such as immediate readout and clinician interaction despite
having to travel to a hospital.
Patient acceptance of cystoscopy was independent of
experience of adverse events relating to the test, suggesting
that the high sensitivity of cystoscopy is of paramount
importance. This is similar to data from colonoscopy, where
patients consider a high sensitivity to be of paramount
importance with risk of adverse effects a secondary concern
[14]. Our data suggest that the prevalence of complications
after cystoscopy are not negligible, with 50% of patients’ self-
reporting haematuria and urinary symptoms after the
procedure and 24% developing UTI requiring antibiotics. This
is considerably higher than previous reports, although it
represents a cumulative experience of patients who have had
multiple cystoscopies and not an incidence rate [7].
We did not observe an association between patient
demographics, education level and clinical-pathological
variables with a lower MAS. In addition, higher disease stage,
grade, actual risk or patient-perceived risk classiﬁcation was
not associated with a higher acceptable sensitivity. The data
indicate that even patients with a lower risk of recurrence or
progression place a high emphasis on accurate cancer
detection. Patients have a perceived beneﬁt for early detection
of recurrence which is clear in high-risk bladder cancer,
although limited data exist to support this in low-risk
cancers. Observational reports suggest that active surveillance
of patients with G1 pTa NMIBC does not increase
Table 4 (continued)
Variables Minimal acceptable sensitivity P
85% 90–95% 96–67% 98% Cystoscopy regardless
Anxiety preceding cystoscopy
Not anxious 27 (54.0) 14 (53.8) 17 (56.7) 32 (56.1) 26 (59.1) 0.972
Somewhat anxious 17 (34.0) 8 (30.8) 10 (33.3) 19 (33.3) 15 (34.1)
Very anxious 5 (10.0) 4 (15.4) 3 (10.0) 6 (10.5) 3 (6.8)
Not known 1 (2.0) 0 (0) 0 (0) 0 (0) 0 (0)
Median (IQR) distance from clinic, miles 6.3 (3.4–11.2) 9.9 (3.8–13.2) 6.1 (3.7–12.6) 5.5 (3.5–11.8) 6.4 (3.3–11.5) 0.726
CIS, carcinoma in situ.
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Table 5 Qualitative analysis for advantages and disadvantages of
cystoscopy, advantages of urine test, active comparison between
cystoscopy and urine test and patient skepticism about urine test.
Advantages of cystoscopy
Visual diagnosis
‘It’s [bladder cancer] caught on camera as it were. You can literally see what’s
going on’
‘I know it’s there and it’s [bladder cancer] staring right at me. You literally see
and discuss what’s there to the chap or women who is doing it’
‘The fact that the camera shows you that thing on the camera and that they show
a scar and they do a grand tour of my bladder. It’s reassuring to see that’
Conﬁdence in diagnostic accuracy
‘I think it’s quite accurate. I would say 95%. It found mine and mine was really
tiny, a couple of mm. They picked it up with the camera and there it was sitting
on the wall. It looked like a little sea anemone’
‘They actually have a camera on the end and its magniﬁed they can see anywhere
in the bladder. So, to me, that’s accurate. If it wasn’t, they wouldn’t have found
mine’
‘I presume it’s because it’s on the screen. I mean I’m not a doctor. I can only
assume that what you see is what you get sort of thing. I mean, there it is. . .. it’s
a cancer. And there is this on the screen I suppose that must be 100%
identiﬁable’
‘To be honest, I think it [cystoscopy] is the only way we can know for sure is
there anything there or not’
Tolerability of cystoscopy
‘Cystoscopy is something I got used to. I have had quite a few of those now and I
accept that fully’
‘Well I don’t like them, but I want to have the most accurate diagnosis possible’
‘If it’s the only way then it’s best to know what’s going on but it’s not exactly a
great overall experience. So, if there’s an alternative obviously, it’s preferable’
‘It is quite invasive, but I think I preferred that because I think then you know
that you got an accurate reading of what’s going on’
‘It’s embarrassing obviously because the thought of exposing yourself to people
but it’s necessary at the same time. So it’s overcoming one thing or the other’
‘Well I don’t suppose there is any other way to do it’
‘You know I really have no dignity left for the start. But you know it’s a small
price to pay’
‘I mean even though a bit of uncomfortable, I don’t mind having the camera
probe’
Instant diagnosis
‘I can literally walk out of there knowing that all is well and that’s very helpful’
‘..that’s [cystoscopy] quite a reassurance to walk out of there thinking that, that
month was all right and we go on from here’
‘. . .. it was a bit daunting, but it was instantaneous. There wasn’t any waiting
around’
‘I can see all in front of me. I guess when someone does a blood test you’ve got
to wait 2–3 weeks for the results to come back’
Qualiﬁed person
‘But if you have a qualiﬁed person who takes a look inside your bladder with a
camera. That’s as good as any I think’
‘They do it at the very professional way and it’s a reassurance for me’
‘. . .the person who did it said it was all clear, so you know. . . nothing else to go
off really’
Disadvantages of cystoscopy
Invasive
‘Well the thought of a camera going inside me from the place they put it in my
urethra. . ..the thought of that going into me does put me off. I don’t really like
that, but you know where else can it go. . .. I feel that the best entry point. . .. not
being cut you open’
‘It was just, obviously the fact that my tube had been invaded with an alien
piece. . . It was just that I have never gone through anything like this before and
it was not what I was expecting. . .’
Adverse events
‘The urine was burning at ﬁrst but that goes away after a couple of hours. . . So,
what I do is I drink plenty of water and just ﬂush it all through’
‘. . ..I did have a bladder problem where I couldn’t control the use of my bladder
whereas when I had a feeling there. . .. I had to pee you know straight away. . .
Rushing to the toilet is most cases’
Table 5 (continued)
‘It was the after effects that went wrong. I couldn’t pass no water but that’s sorted
itself out now’
‘Well it must have been sort of the ﬁrst couple of passes, a little bit of blood
came out after that, it was okay’
Embarrassing
‘It’s embarrassing obviously because the thought expose yourself to people but it’s
necessarily at the same time. So it’s overcoming one thing or the other’
‘Again it’s a psychological embarrassing feeling that well okay I’m exposing
myself to somebody.. ’
‘You know I really have no dignity left for the start’
Operator dependent
‘. . .the doctor was being shown how to use a new machine. Two other people
watching and a lady showing her what to do you know. It didn’t bother me at the
time but you know I was a bit sore. I was well quite sore after that. It took me a
week or so to get myself right with it. Now the second, the next time I went for
it, it was the registrar. . . I couldn’t believe it. He did it and he said right okay
thank you. So, I said, “are we done” and he said, “yeah”. With the other lady, it
seemed like an hour, but this was probably about 10 min. Well, it was only
minutes with this chap. I just walked out as good as when I went in’
Advantages of urine test
No adverse events
‘If they can ﬁnd it all the way through urine test. . . that would be a much better
and more comfortable way of checking’
‘..certainly more convenient and less uncomfortable for the patient’
Less intrusive
‘. . .if it helps detect cancer in a less invasive way I suppose it is good’
‘.. there’s less interference in there,. . . I’ve always been a bit sore when I’ve had
one [cystoscopy]. You know you go for a wee and it sore’
‘. . . the urine test is much less alarming thing to do than going in for a
cystoscopy’
‘. . . reduce the level of personal invasions’
Quicker treatment time
‘. . .where you could start treatment early I think would be a great advantage’
Reduce patient embarrassment
‘It’s not a very nice experience you know. . .there were two young girls in their
20s. Nurses. It’s not a nice experience anyway but having that it’s a bit. . .. you
know, not nice’
Convenience
‘I suppose logically the urine test if it’s proven is a bit easier’
‘. . . it would be a simple thing to collect some urine and see you could determine
whether there were cancer cells, where you could start treatment early I think
would be a great advantage’
‘Obviously a lot easier than the cystoscopy’
‘. . .reduce inconveniencing the patient’
‘. . .if I could ﬁnd out everything from urine sample then it would be a lot easier
because you don’t have to spend any time in the hospital’
‘..certainly more convenient and less uncomfortable for the patient’
Active comparison between cystoscopy and urine biomarker
‘Given the particular cancer I have is high grade. . .signet cell variation. . .. I’d be
wary of it [urine biomarker]. I need more reassurance as I am not out of the
woods yet Because I’m just a year into a disease. Everything is happening well for
me at present the treatment seems to be working well for me and I’m very
relaxed and conﬁdent about it. I would need some reassurance that this is as good
or comparable’
‘Well I am not fussed either way. . .that [urine biomarker] would be an easier way
obviously instead of going through cystoscopy but I don’t know how accurate it is
going to be. . .If you do pull it off then all well and good’
‘I’ll look at it differently. You know I’m 79, a realist. . . I am content, happy with
the treatment. And the cystoscopy is something that has become part of my life
and I’m content with that’
‘Well I still would like it [urine biomarker] to be up to 99 percent. It has to be.
You can’t mess with peoples’ life. You can’t have 70–78% and then it’s quite
possible you missed it. You know. if its 99–99.5 percent, at least you are in the
right area with cystoscopy’
‘I think it must be comparable to the cystoscopy. Otherwise, the numbers that
could slip through would be unfortunate’
‘Well there is no 100% guarantee here, but a high percentage would be good’
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oncological risk [15]. Distance to hospital was not a factor, as
patients value the visit to hospital and prefer seeing a
clinician as it reassures them.
Two previous studies have reported the MAS required of a
urine biomarker to replace cystoscopy in patients with
NMIBC in the surveillance setting. Vriesema et al. [16]
surveyed 102 patients with at least 12 months’ follow-up and
reported that 89% of patients would not accept a urinary
biomarker with a sensitivity of <90%. Yossepowitch et al. [17]
assessed the preference of 200 patients undergoing check
cystoscopies at various time points and reported that 75% of
patients would not accept a biomarker with an accuracy of
<95%. Both studies reported that men were willing to accept
a marginally lower MAS [16,17]. The study by Vriesema et al.
and Yossepowitch et al. [16,17] report that patients who were
older (>67 years) and those who experienced a higher pain
intensity after cystoscopy, respectively, were signiﬁcantly more
likely to accept a lower sensitivity.
The present study differs from these two studies. Besides reporting
the MAS of a urine biomarker that patients were prepared to
accept, we also investigated the reasons for patients’ preference for
cystoscopy or urine biomarker using qualitative and quantitative
methods. We did not ﬁnd any variables associated with a lower
MAS. A reason for this may be the fact that patients in the present
study completed the questionnaire 6 months following a cancer
diagnosis, suggesting a shorter time interval compared with the
other two studies (minimum of 12 months [16] and median
follow-up of 50 months [17]). The fear of cancer recurrence may
be prioritized over pain attributed to cystoscopy [16,17]. Patients
in both studies also did not experience the use of a urine
biomarker and assumed that cystoscopy was 100% sensitive,
which it is not in clinical practice.
Patients valued the visual element of cystoscopy as this was
something they could relate to, and the absence of a visual
diagnosis of cancer provides signiﬁcant reassurance. Patients
are aware that cystoscopy is the gold standard diagnostic test
for bladder cancer surveillance and perceived a urine test as
experimental, which may have introduced bias; however, if
the sensitivity of a urine test were proven to be close to
cystoscopy, 78.7% of patients would be happy to accept a
urine test at intervals.
Limitations of the present study should be acknowledged.
Complications such as UTI requiring antibiotics after cystoscopy
were self-reported by patients and not conﬁrmed by urine
culture. In addition, the present study was not designed to
report the incidence rate of UTI per cystoscopy performed, but
to identify correlation between patient-reported and perceived
adverse events and acceptability of a urine biomarker test.
Further, all patients had at least one general anaesthetic for
cystoscopy or transurethral resection of bladder cancer and,
while the questionnaire was intended to gauge patient’s
perspectives on surveillance ﬂexible cystoscopy, the patient’s
overall experience with any cystoscopy may have had an
inﬂuence in shaping their opinion. It was assumed that patients
would comprehend the questionnaire when completing it, as no
medical terminology was used. Although all patients provided a
urine sample for biomarker testing, they were not provided with
the results of the biomarker. The knowledge of the biomarker
results combined with a patients’ experience with cystoscopy
may affect the MAS. Finally, cystoscopies were nearly universally
performed by urology trainees/residents and in more
experienced hands, adverse events and patient’s acceptability
may be improved.
In conclusion, we report that patients with NMIBC valued
the high sensitivity that cystoscopy accords despite the
reported patient discomfort and adverse events experienced.
Patients considered any diagnosis of cancer to be signiﬁcant
and were not willing to compromise on the diagnostic ability
of a test. Hence, a diagnostic sensitivity of any urine
biomarker must be close to that of cystoscopy before patients
are prepared to accept it over cystoscopy.
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